There is a meeting at 18:00 on 19 February 2026, US ET (10:00am Friday 20 February Sydney) by Medicare Administrative Contractor (MAC) Novitas to consider the evidence for urine biomarkers in patients with hematuria. This meeting is most likely to determine the draft Local Coverage Determination (LCD) covering Medicare reimbursement of PEB's urine diagnostic test Cxbladder. Translated, a positive conclusion could give a massive boost to the share price that has been badly impacted by the previous withdrawal of medicare support.

The meeting should last about two hours, with access available via:

https://fcso.webex.com/weblink/register/red3f833b75a2f3922d04ada5d71a6aee

The securities of Pacific Edge Limited(‘PEB’) will be placed in trading halt at the request of PEB, pending it releasing an announcement. Unless ASX decides otherwise,the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 3 June 2025or when the announcement is released to the market.

Yesterday PEB, the NZ headquartered and ASX listed company announced:

“Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today notes that Novitas, the Medicare Administrative Contractor with jurisdiction for our US laboratory, on Thursday 9 January 2025 finalized a non-coverage determination that would end reimbursement for Cxbladder Triage, Detect and Monitor by Medicare”.

With the already sick PEB share price approaching stage IV terminal, on yesterdays news PEB dropped a further 60%.  Looks like PEB joins RHY (bowel cancer diagnosis), BDX (breast cancer diagnosis) and PIQ (Diabetic Kidney disease and endometriosis) as a full blown ASX Cancer Cluster. 

Sadly for everyone, no cure in sight.